Index

A
Abuse, topical steroids
Africa perspective
adverse effects, 230
allergic dermatitis, 233, 234
bleaching creams, 229, 230
complications, 230
Cushing syndrome, 234, 235
dyschromia, 233, 234
gluteal granuloma infantum, 234
hypertrichosis, 234
pustulosis psoriasis and the dermocorticoids, 234–235
skin atrophy, 233, 234
skin infections, 230–232
striae distensae, 232–233
Australian perspective
atopic dermatitis, 238
attitudes and behaviour, 239–240
eczema, 238
guidelines, 238
overuse, 238–239
research, 238
use, 237–238
in Bangladesh
bleaching effects, 201
cosmetics, 201
creams, 201
effect and potency, 198
grades, 198
improper and wrong use, 201
misuse, 200
side effects/adverse effects, 198–202
use for, 197, 198
clinical manifestations, 133
cosmetic cream
epidemiology, 130–131
response, 133–134
education, 304
epidemiology of, 130–131
fairness craze, 302–303
dermatologists, 304
governmental agencies, 305
industry, 305
Japanese perspective
advocacy, 226
atopic dermatitis, Japanese Dermatological Association Guidelines, 226
doctors prescription, 224
Internet use, 227
lawsuit, 225
media and topical steroid use, 225
medical malpractice claims, 225–226
NHI system and drug price margins influence, 224–225
overservicing, 224
over the counter drugs, 223, 226
precautions, over the counter topical steroids, 223–224
lupus vulgaris, 322
Majocchi’s granuloma, 321, 324
malassezia folliculitis, 321

© Springer Nature Singapore Pte Ltd. 2018
K. Lahiri (ed.), A Treatise on Topical Corticosteroids in Dermatology,
DOI 10.1007/978-981-10-4609-4
Abuse, topical steroids (cont.)
menacing proportions, 301
in Middle East, 206
adult population, 206–207
education, 207
pediatric population, 206
pigmentary disorders, 207
prescription, 207
in Nepal, 190–191
disease distribution, 194
facial dermatosi, 194, 195
over the counter drugs, 191
patient perspective, 191
significant amount, 195
steroid-induced dermatosis, 191–193
steroids, 194
tinea incognito, 192–194

procedural techniques
acne and acneiform eruptions, 278–280
telangiectasia and steroid-induced rosacea, 280
psoriasis Koebnerizing, 322
regulatory aspects
Africa, jungle of law, 288
blanket ban, 287
COOT cocktail, 286
drug control authorities, 284
European Union legislation, 288
fairness, misuse of steroid creams, 287
fixed drug combinations, 284
imitators, 286–287
Indian drug regulation scene, 284–285
irrational steroid, plethora of, 285–286
menace, 288
point of sale, 288
price control angle, 287
schedule H tragedy and legislation, 285
response, 133–134
side effects and management, 278
Southeast Asia, 210
acneiform eruptions, 213, 215–216
adverse reactions, 221
axillary regions, 212
Cushing’s syndrome, 221
factors, 210–211
fungal infections, 217–219
furunculosis and folliculitis, 217, 219, 220
guidelines, 221
inner arms, striae, 212
perilesional hypopigmentation, 217, 220
perioral dermatitis, 213, 217
potency, 221
psoriasis teenage, 211
psoriatic Indonesian patient, 212
psoriatic Singaporean patient, 211
skin atrophy, 212, 215
telangiectasia, 212, 214
tinea faciei, 322, 323
topical steroid-induced striae, 323
TSDF, 302
ulceration, 322, 324
widespread tinea, 323
Acne, 231, 233, 278–280
Acneiform eruption
abuse
Africa, 231, 232
Nepal, 193
Southeast Asia, 213, 215–216
adverse effects, 113
management, procedural techniques, 278–280
topical side effects, 255
TSDF, 141
Addiction, 123, 133, 148, 262, 284. See also Topical
corticosteroid addiction (TCA)
Addison’s disease, 4
ADR. See Adverse drug reaction (ADR)
Adrenocortical insufficiency, 312
Adverse drug reaction (ADR), 19–20, 292
Africa, topical steroid abuse
adverse effects, 230
allergic dermatitis, 233, 234
bleaching creams, 229, 230
complications, 230
Cushing syndrome, 234, 235
dyschromia, 233, 234
gluteal granuloma infantum, 234
hypertrichosis, 234
pustulosus psoriasis and the dermocorticoids,
234–235
skin atrophy, 233, 234
skin infections, 230–232
striae distensae, 232–233
AIBDs. See Autoimmune blistering diseases (AIBDs)
Allergic contact dermatitis, 145, 233, 234
Alopecia areata, 65, 103
intralesional steroids, 103–104
topical corticosteroids, 104
Alopecia areata (AA), 32–33
Androgenetic alopecia, 105
Anogenital pruritus, 65
Antifungal shampoos, 102–104
Arciform lesions, 154–155
Atopic dermatitis (AD)
dermatological indications and usage, 28–29
eczematous lesion of, 111
Japanese Dermatological Association Guidelines, 226
phobia, 268
rational use, 120
research, 238
RSS, 170
Atrophogenesis, 166
Atrophy
alopecia areata, intralesional steroids, 103
genital dermatosis, 165
side effects, 253–254
dermal atrophy, 254
epidermal atrophy, 254
purpura and easy bruising, 254
stellate pseudoscars, 254–255
Index

striae, 254
telangiectasia, 254
TSDF, 146
Australia, TCS use and overuse
atopic dermatitis, 238
attitudes and behaviour, 239–240
eczema, 238
guidelines, 238
overuse, 238–239
research, 238
use, 237–238
Autoimmune blistering diseases (AIBDs), 92
adrenal suppression, 97
bullous pemphigoid, 93
evidence, 93–94
guidelines, 94–95
international management, 95
EBA, 97
linear IgA disease, 97
MMP, 96
pemphigoid gestationis, 96–97
pharmacology
chemical structure, 92
mechanism of action, 92–93
PV and PF, 95–96
side effects, 97–98
Burns, 35

C
Calcineurin inhibitors, 166
Candida albicans, 257
Candidial balanoposthitis, 161–162
Cayenne pepper spots, 162
Central centrifugal cicatricial alopecia (CCCA), 106
Chemical peel, 279, 281
Children, pediatric age group, 110–111
adverse effects, 113–114
measurement, 115
misuse of, 114–115
use of, 111–113
Cicatricial alopecias, 105–106
Circumcision, 166
CLE. See Cutaneous lupus erythematosus (CLE)
Clobetasol-ofloxacin-ornidazole and terbinafine (COOT) cocktail, 286
Clobetasol propionate (CP), 82, 92, 93, 106
Clocortolone pivalate, 6
Committee on the Safety of Medicines (CSM), 293
Compound F. See Hydrocortisone
Contact dermatitis (CD), 30
Contact hypersensitivity, 165–166
Contact sensitization, 257–258
COOT cocktail. See Clobetasol-ofloxacin-ornidazole and terbinafine (COOT) cocktail
Corporis, 153
Corticosteroid-binding globulin (CBG), 82
Cortisol, 13, 26, 27, 83, 172, 176, 252, 271
Cortisone, 3, 4, 172
Cosmetics
abuse
epidemiology, 130–131
response, 133–134
popularity, TCS, 131–132
Council for International Organizations of Medical Sciences (CIOMS), 294
Counselling, 115
Cream, 18–19, 102, 119
Crusted scabies, 232
Cushing’s syndrome, 221, 234, 235, 244, 312
Cutaneous syndrome, 221, 234, 235, 244, 312
Cutaneous lupus erythematosus (CLE), 33, 65
Cutaneous sarcoidosis, 36, 63
Cutaneous T-cell lymphoma (CTCL), 62

B
Bacterial infections, 217, 231, 232, 256–257
Balanitís xerotica obliterans, 162–163
Bananosthisitís, 161–162
Bangladesh, topical corticosteroid abuse
bleaching effects, 201
cosmetics, 201
creams, 201
effect and potency, 198
grades, 198
improper and wrong use, 201
misuse, 200
side effects/adverse effects, 198–202
use for, 197, 198
Betamethasone, 6, 13
Betnovate C, 287
Black Triangle Drugs, 293
Blistering diseases
adrenal suppression, 97
bullous pemphigoid, 93
evidence, 93–94
guidelines, 94–95
international management, 95
EBA, 97
linear IgA disease, 97
MMP, 96
pemphigoid gestationis, 96–97
pharmacology
chemical structure, 92
mechanism of action, 92–93
PV and PF, 95–96
side effects, 97–98
Blistering disorders, 33–34
Blue card, 239
Breastfeeding, 26–27, 88, 89
Bullous pemphigoid (BP), 93
evidence, 93–94
experimental model, 92
guidelines, 94–95
international management, 95
randomized controlled trials, 63
Burns, 35
D
Delayed wound healing, 258
Demodex folliculorum, 256
Dermal atrophy, 182, 254
Dermatoses, 4, 6, 88, 89, 113, 118, 160, 256
Dermocorticoids, 234–235
Discoid lupus, 106
Double-edged tinea, 154
Drug price margin, 224–225
Drugs and Cosmetics Act, 285
Drugs and Magic Remedies (Objectionable Advertisement) Act, 302
Drug withdrawal syndrome, 238–239
Dumbbell-shaped large annular lesions, 154–155
Dyschromia, 233, 234
E
Eczema, 238
randomized controlled trials, 43–50
systematic review, 43
EPDS. See Erosive pustular dermatosis of the scalp (EPDS)
Epidermal atrophy, 254
Epidermolysis bullosa acquisita (EBA), 97
Erosive pustular dermatosis of the scalp (EPDS), 106
Erysipelas, 233
Erythema, 18, 113, 139, 199
Ethics
issues
beneficence vs. autonomy, 75–76
non-malfeasance, 75
patient autonomy, 75
truth telling, 75
use of
amount, frequency, and duration, 77
corticosteroid allergy, being aware of, 77
diagnosis, 76
effective communication, 77–78
exit strategy, 77
molecule and delivery system, 76
patient, 76–77
prevention and modifiable factors, focusing, 77
European Medicines Agency (EMA), 293
Europe, pharmacovigilance, 293
Evidence based approach
bullous pemphigoid, 63
cutaneous sarcoidosis, 63
eczema, 43–50
hand eczema, 63–64
infantile hemangiomas, 64
lichen planus, 60–62
miscellaneous conditions, 65
mycosis fungoides, 62–63
pregnancy and lactation, 65
psoriasis, 53–60
vitiligo, 50–52
F
Fetal growth restriction, 84
Fingertip unit (FTU) method, 77, 111, 120, 224
Fluocinolone acetonide, 5, 103–105
Fluorinated agents, 4–5
9α-Fluorohydrocortisone acetate, 4
Folliculitis, 104, 217, 219, 220
Frontal fibrosing alopecia (FFA), 106
FTU method. See Fingertip unit (FTU) method
Fungal infections, 217–219
Furunculosis, 217, 219, 220
G
Gels, 19, 102, 119
Genital dermatosis
atrophy, 165
calcineurin inhibitors, 166
circumcision, 166
contact hypersensitivity, 165–166
genitocrural region, microenvironment
balanitis xerotica obliterans, 162–163
balanoposthitis, 161–162
females, 160–161
genital pruritus, 164
LSA, 162
male, 160
plasma cell balanitis/Zoon’s balanitis, 162
plasma cell vulvitis, 163
pseudoepitheliomatous micaceous and keratotic balanitis, 163
vulvar lichen sclerosus atrophicus, 163–164
side effects, 164–165
Genital pruritus, 164
Genitocrural region, microenvironment
balanitis xerotica obliterans, 162–163
balanoposthitis, 161–162
females, 160–161
genital pruritus, 164
LSA, 162
male, 160
plasma cell balanitis/Zoon’s balanitis, 162
plasma cell vulvitis, 163
pseudoepitheliomatous micaceous and keratotic balanitis, 163
vulvar lichen sclerosus atrophicus, 163–164
Gluteal granuloma infantum, 234
Granulomatous diseases, 36
Great Depression, 2, 3
H
Haemangiomas, 34
Hair and scalp disorders
alopecia areata, 103
intralesional steroids, 103–104
topical corticosteroids in, 104
androgenetic alopecia, 105
categories, 102
cicatricial alopecias, 105–106
EPDS, 106
formulations, 102–103
polyamide, 106
polymeric nanocarriers, 106
scalp psoriasis, 104–105
seborrhoeic dermatitis, 104
Hand eczema, 30, 63–64
Herpetic balanitis, 161–162
Hirsutism, 141, 142, 280–281
HPA axis. See Hypothalamic pituitary-adrenal (HPA) axis
Human vasoconstriction assay, 7, 14
Hydrocolloid dressing, 31
Hydrocortisone, 3–5, 25, 30, 35, 87, 92, 130, 138, 163, 239, 252, 262, 284, 310
11β-Hydroxysteroid dehydrogenase (11βHSD), 26, 82, 83, 172, 176
Hyperglycemia, 246
Hyperlipidemia, 246
Hyperpigmentation, 75, 132, 144, 193, 233
Hypertension, 246
Hypertrophic scars, 35
Hypopigmentation, 103, 144, 157, 182
Hypothalamic pituitary–adrenal (HPA) axis, 244, 245
I
Iatrogenic Cushing’s syndrome, 244, 245
ICH. See International Council for Harmonisation (ICH)
Idiopathic urticaria, chronic, 35
ILS. See Intralesional steroid (ILS)
Imbricated tinea, 324
India
regulatory aspects
blanket ban, 287
COOT cocktail, 286
drug control authorities, 284
European Union legislation, 288
fairness, misuse of steroid creams, 287
fixed drug combinations, 284
imitators, 286–287
Indian drug regulation scene, 284–285
irrational steroid, plethora of, 285–286
menace, 288
point of sale, 288
price control angle, 287
schedule H tragedy and legislation, 285
topical steroid abuse, 180
awareness campaign, 183–184
effects, 183
face, side effects, 182
historical aspects, 180
indications, misuse, 181
less-known cutaneous side effects, 183
magnitude, 181–182
measurement, 186
misuse, reasons, 180
ocular complications, 183
population, 181
sales, 181
side effects, 182
stages, misuse, 180–181
studies on, 185
systemic side effects, 183
task force, 184–185
treatment, 186
types, 181
Infantile hemangiomas, 64
Infestations, 257
Inflammatory dermatoses, 83
Intense pulsed light (IPL), 280
International Council for Harmonisation (ICH), 294
International Topical Steroid Addiction Network (ITSAN), 312–313
associations, 313–314
fixed drug combinations, 310
mission, 313
newsletter, 314–315
RSS, 313
Intertrigo, 34
Intralesional steroid (ILS), 28, 35
ITSAN. See International Topical Steroid Addiction Network (ITSAN)
J
Japan
pharmacovigilance, 293
topical steroid abuse
advocacy, 226
atopic dermatitis, Japanese Dermatological Association Guidelines, 226
doctors prescription, 224
Internet use, 227
lawsuit, 225
media and topical steroid use, 225
medical malpractice claims, 225–226
NHI system and drug price margins influence, 224–225
overservicing, 224
over the counter drugs, 223, 226
precautions, over the counter topical steroids, 223–224
K
Keloid, 35
Keratinocyte, 18, 105, 172, 254
Keratotic balanitis, 163
Ketoconazole, 104
Kligman formula, 132, 148, 181, 185
L
Labial adhesion, 34–35
Lactation
pros and cons of
bioavailability, 88
hydrocortisone, 87
preparation, potency ranking, 88
safety of, 88–89
randomized controlled trials, 65
Langerhans cells, 16
Laser therapy, 281
Leucotrichia, 112
Lichen planus (LP), 32
hypertrophicus, 112
randomized controlled trials, 60–62
well-defined violaceous plaque of, 112
Lichen sclerosus, 35, 166
Lichen sclerosus et atrophicus (LSA), 162
Lichen simplex chronicus (LSC), 30
Linear IgA disease, 97
Lotion, 19, 102, 119
LSA. See Lichen sclerosus et atrophicus (LSA)
Lupus vulgaris, 322
Lymphocytic microfolliculitis, 105

M
Majocchi’s granuloma, 257, 321, 324
Malassezia folliculitis, 321
Male genital dermatophytosis, 155–156
Marker degradation, 3
Medicines and Healthcare Products Regulatory Agency (MHRA), 293
MedWatch, 293
Melasma, 35, 65
Metabolic disorders, 246
Microenvironment, genitocrural region
balanitis xerotica obliterans, 162–163
balanoposthitis, 161–162
females, 160–161
genital pruritus, 164
LSA, 162
male, 160
plasma cell balanitis/Zoon’s balanitis, 162
plasma cell vulvitis, 163
pseudoepitheliomatous micaceous and keratotic balanitis, 163
vulvar lichen sclerosus atrophicus, 163–164
Middle East, topical corticosteroid use, 206
adult population, 206–207
education, 207
pediatric population, 206
pigmentary disorders, 207
prescription, 207
Minoxidil, 105
MMP-9, 92
Mometasone furoate, 64, 106
Mucocele, 36
Mucous membrane pemphigoid (MMP), 96
Multiple small annular lesions, 154–155
Mycoses, 230–231
Mycosis fungoides, 62–63

N
National Health Insurance (NHI) system, 224–225
Nepal, topical steroid abuse, 190–191
disease distribution, 194
facial dermatosis, 194, 195
over the counter drugs, 191
patient perspective, 191
significant amount, 195
steroid, 194
steroid-induced dermatosis, 191–193
tinea incognito, 192–194
Neutrophils, 92
NHI system. See National Health Insurance (NHI) system
Nitric oxide (NO), 264
Nitric oxide synthetase, 17
Nitro-glucocorticoids, 20
Nodulocystic acne, 36

O
Occlusive dressing therapy, 28
Ocular adverse effects, 246
Ointments, 19, 102, 119
Orofacial cleft, 84

P
Panderm Plus cream, 181
Papules, 139
Parasites, 231
Pemphigoid gestationis (PG), 96–97
Pemphigus foliaceus (PF), 95–96
Pemphigus vulgaris (PV), 95–96
Perianal inflammation, 34
Perilesional hypopigmentation, 217, 220
Perioral dermatitis, 65, 144, 213, 217, 231, 232, 255–256
Peristomal dermatoses, 30
Pharmaceuticals and Medical Devices Agency (PMDA), 293
Pharmacology
ADRs, 19–20
anti-inflammatory and immuno-suppressant effects, 16–18
anti-proliferative action, 18
classification, 14, 15
contraindications, 20
formulations, 18–19
geriatric and paediatric patients, 20
mechanism of action, 15–16
potency, 13–14
pregnancy and lactation, 20
selection and use, 19
structure-activity relationship, 12–13
therapeutic indications, 18
vasoconstrictor action, 18
Pharmacovigilance, 292
active surveillance, 292
ADR, 292
adverse event, 292
CIOMS, 294
in Europe, 293
ICH guidelines, 294
in Japan, 293
passive surveillance, 292
in special population, 293
spontaneous reporting, 293
in US, 293
VigiBase, individual case safety report, 295–299
WHO, 293–294
Phimosis/labial adhesion, 34–35
Phobia
aetiology, 268
consequences, 268
management, 268–269
Phospholipase A_, 16
Photodermatitis, 199
Photosensitive eczema, 30
Photosensitivity, 146, 186, 200, 256, 273
Pigmentary disorders, 207
Pityriasis alba, 30
Plaque psoriasis, chronic, 112
Plasma cell balanitis, 162
Plasma cell vulvitis, 163
Polyamide, 106
Polymeric nanocarriers, 106
Post-inflammatory hypopigmentation, 114
Prednisolone, 13
Pregnancy
  cutaneous absorption and bioavailability in, 82
  indications, 83
  metabolism, 82–83
  randomized controlled trials, 65
  recommendations, 84–85
  safety profile
    data, 83
    effects of, 83–84
    fetal death, 84
    fetal growth restriction, 84
    orofacial cleft, 84
    preterm delivery, 84
Preterm delivery, 84
Primary cicatricial alopecias (PCA), 105–106
Profuse tinea, 231
Propionibacterium acnes, 256
Psoriasis, 31
  children with, 31–32
  Koebner phenomenon, 322
  randomized controlled trials, 53–60
Purpura, 254
Pustules, 140
Pustulosis psoriasis, 234–235
R
Rebound phenomenon, 256
Red scrotum syndrome, 256
Red skin syndrome (RSS), 42, 169–170, 313
  causes, 172
    cortisol levels and progression, epidermis, 176
    epidermal changes, 172, 173
    epidermis with immunostaining, 172, 174–175
    clinical manifestation, 170–172
    management, 177
Rosacea, 193, 231, 232, 255–256
Rosacea-like dermatitis, 255, 272
RSS. See Red skin syndrome (RSS)
S
Salicylic-mandelic acid, 279
Sarcoidosis, 36, 63
Scalp disorders
  alopecia areata, 103
  intralessional steroids, 103–104
  topical corticosteroids in, 104
  androgenetic alopecia, 105
  categories, 102
  cicatricial alopecias, 105–106
  EPDS, 106
  formulations, 102–103
  polyamide, 106
  polymeric nanocarriers, 106
  scalp psoriasis, 104–105
  seborrheic dermatitis, 104
  Scalp psoriasis, 104–105
  Scarring alopecia, 106
  Schedule H, 74, 124, 182, 285, 304, 305
  Seborrheic dermatitis (SD), 29, 65, 104
  Selective glucocorticoid receptor agonists (SEGRAs), 20, 247
  SIL. See Steroid-induced lipoatrophy (SIL)
SIR. See Steroid-induced rosacea (SIR)
Skin
  atrophy, 199, 233, 234
  bleaching creams, 288
  infection
    bacterial, 231, 232
    mycoses, 230–231
    parasites, 231
    viral, 232
  perlesional hypopigmentation, 217, 220
  psoriasis teenage, 211
  psoriatic Indonesian patient, 212
  psoriatic Singaporean patient, 211
  skin atrophy, 212, 215
  telangiectasia, 212, 214
Staphylococcus aureus, 29, 122, 256–257
Stellate pseudoscars, 254–255
Steroid acne, 198
Steroid-damaged skin, treatment
  saline injections, 273
  SIL, 273, 274
  SIR, 272
  steroid-induced atrophy, 272–273
  steroid-induced striae, 273
Steroid dermatitis, 133
Steroid-induced atrophy, 113, 272–273
Steroid-induced erythema, 113
Steroid-induced hypertrichosis, 114
Steroid-induced lipoatrophy (SIL), 273, 274
Steroid-induced rosacea (SIR), 272, 280
Steroid-induced striae, 273, 323
Steroid-modified tinea
   clinical presentations, 152
      arciform lesions, 154–155
      double-edged tinea, 154
      dumbbell-shaped large annular lesions, 154–155
      eczematous lesions, 154
      larger-sized lesions, 152, 153
      male genital dermatophytosis, 155–156
      multiple annular lesions, 154–155
      multiple small annular lesions, 154–155
      prominent striae and hypopigmentation, 157
      tinea corporis, erythrodemic variant, 157
      tinea cruris and corporis, 153
      tinea faciei, 156, 157
      tinea pseudoimbricata, 153–154
   morphological patterns, 152
   veritable epidemic, 152
Steroid preatrophy, 28
Steroid rosacea, 183
Steroid withdrawal syndrome, 238
Striae, 146, 254, 281
distensae, 232–233
Sulfonated shale oil cream, 264
Sulzberger, M.B, 4
Superficial dermatophytosis
   clinical presentations, 152
      arciform lesions, 154–155
      double-edged tinea, 154
      dumbbell-shaped large annular lesions, 154–155
      eczematous lesions, 154
      larger-sized lesions, 152, 153
      male genital dermatophytosis, 155–156
      multiple annular lesions, 154–155
      multiple small annular lesions, 154–155
      prominent striae and hypopigmentation, 157
      tinea corporis, erythrodemic variant, 157
      tinea cruris and corporis, 153
      tinea faciei, 156, 157
      tinea pseudoimbricata, 153–154
   morphological patterns, 152
Superficial infantile cutaneous hemangiomas, 64
Symptomatic oral LP, 60

T
Tachyphylaxis, 197
Tar shampoos, 102
TCA. See Topical corticosteroid addiction (TCA)
TCP. See Topical corticosteroid phobia (TCP)
TCS. See Topical corticosteroid (TCS)
Telangiectasia, 142, 193, 212, 214, 254, 280
Tinea corporis, 152, 157, 193, 218, 323
Tinea cruris, 153
Tinea faciei, 156, 157, 322, 323
Tinea incognita, 154, 230
Tinea incognito, 113, 143, 192–194
Tinea pseudoimbricata, 153–154, 230, 231
Topical corticosteroid (TCS), 24
absorption, 26
administration frequency and treatment duration, 27–28
chemical structure, 24
combination, 27
ethical issues
   beneficence vs. autonomy, 75–76
   non-malfeasance, 75
   patient autonomy, 75
   truth telling, 75
ethical use
   amount, frequency, and duration, 77
corticosteroid allergy, being aware of, 77
diagnosis, 76
effective communication, 77–78
exit strategy, 77
molecule and delivery system, 76
patient, 76–77
prevention and modifiable factors, focusing, 77
evolution
   adrenal extracts, 2
   betamethasone, 6
clocortolone pivalate, 6
   commercial side, 3–4
   and development, 6–7
   first topical use, 4
   fluorinated agents, 4–5
   local and systemic absorption, 6
   planned serendipity, 2–3
   Sulzberger and Witten, 4
ILS administration, 28
indications
   alopecia areata, 32–33
   atopic dermatitis, 28–29
   blistering disorders, 33–34
   burns, 35
   children with psoriasis, 31–32
   chronic idiopathic urticaria and urticaria pigmentosa, 35
   CLE, 33
   contact dermatitis, 30
   granulomatous diseases, 36
   haemangiomas, 34
   hand eczema and pityriasis alba, 30
   intertrigo and perianal inflammation, 34
   keloid and hypertrophic scars, 35
   lichen planus, 32
   lichen sclerosus, 35
   LSC, 30
   melasma, 35
   mucocele, 36
   nodulocystic acne, 36
   peristomal dermatoses, 30
   phimosis/labial adhesion, 34–35
   photosensitive eczema, 30
   pretreatment, 35–36
   psoriasis, 31
   sarcoidosis, 36
   seborrhoeic dermatitis, 29
   vitiligo, 33